Literature DB >> 3653231

Pharmacokinetics and systemic availability of the antihypertensive agent indoramin and its metabolite 6-hydroxyindoramin in healthy subjects.

D M Pierce1, S M Abrams, R A Franklin.   

Abstract

We have studied the pharmacokinetics and absolute systemic availability of indoramin (50 mg) given orally in solution or as a tablet with reference to intravenously administered drug (0.15 mg/kg) in 9 healthy volunteers. After intravenous administration the median apparent volume of distribution was 6.3 l X kg-1, plasma clearance was 20.0 ml X min-1 X kg-1, and terminal half-time was 4.1 h. When given by tablet indoramin was absorbed with moderate rapidity, with a median tmax of 1.5 h. The median systemic availability was 24%. After oral administration in solution the drug was more rapidly absorbed, with a median tmax of 1.0 h (p less than 0.01). The median systemic availability was 43% (15-85%). Plasma concentrations of an active metabolite, 6-hydroxyindoramin, after single oral doses in either dosage form, were of a similar order to those of unchanged drug and fell with similar rapidity. After intravenous administration, however, concentrations of the metabolite were negligible.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3653231     DOI: 10.1007/BF02455999

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Labetalol: bioavailability, drug plasma levels, plasma renin and catecholamines in acute and chronic treatment of resistant hypertension.

Authors:  W J Louis; N Christophidis; M Brignell; V Vijayasekaran; J McNeil; F J Vajda
Journal:  Aust N Z J Med       Date:  1978-12

3.  Pharmacokinetics of intravenous indoramin in middle-aged male and female volunteers.

Authors:  H M Norbury; R A Franklin; P K Marrott; S J Warrington
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Pharmacokinetics of indoramin in man.

Authors:  G H Draffan; P J Lewis; J L Firmin; T W Jordan; C T Dollery
Journal:  Br J Clin Pharmacol       Date:  1976-06       Impact factor: 4.335

5.  Pharmacokinetics of oral indoramin.

Authors:  G N Volans; D Jeffereys; A N Latham; T Frost
Journal:  Curr Med Res Opin       Date:  1982       Impact factor: 2.580

6.  Determination of therapeutic concentrations of indoramin by liquid chromatography with fluorimetric detection.

Authors:  A J Swaisland
Journal:  Analyst       Date:  1981-06       Impact factor: 4.616

Review 7.  Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.

Authors:  G Johnsson; C G Regàrdh
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

8.  The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses.

Authors:  R G McAllister; E B Kirsten
Journal:  Clin Pharmacol Ther       Date:  1982-04       Impact factor: 6.875

9.  Studies on the metabolism of the new anti-hypertensive agent, indoramin, in man.

Authors:  R A Franklin; P Robson; D Stevenson
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

10.  Pharmacokinetics of oral indoramin in elderly and middle-aged female volunteers.

Authors:  H M Norbury; R A Franklin; P K Marrott; S J Warrington
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

View more
  5 in total

1.  The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine.

Authors:  D M Pierce; S E Smith; R A Franklin
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

2.  Intra- and inter-subject variation in the pharmacokinetics of indoramin and its 6-hydroxylated metabolite.

Authors:  D M Pierce; S M Abrams; R A Franklin
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 3.  Metabolites of antihypertensive drugs. An updated review of their clinical pharmacokinetic and therapeutic implications.

Authors:  A Ebihara; A Fujimura
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

Review 4.  Individual variation in first-pass metabolism.

Authors:  Y K Tam
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of vasodilators. Part II.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-07       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.